Dermata Therapeutics, Inc. 8K

Dermata Therapeutics reported 2025 financial results and detailed its strategic pivot to launch Tome-branded DTC skincare products beginning mid‑2026, supported by recent financings and a new marketing leadership hire.

On March 26, 2026, Dermata Therapeutics, Inc. reported its financial results for the year ended December 31, 2025 and provided a corporate update highlighting its ongoing strategic pivot from prescription dermatology to direct-to-consumer (DTC) skincare products under the new Tome brand. The company reiterated that it announced this shift in September 2025, is preparing for a mid‑2026 launch of its first DTC product, the Foundational Treatment, followed shortly by a Clearing Treatment acne product, and has hired a Vice President of Marketing, Kyra Peckaitis, to lead brand development and commercialization. Dermata disclosed that it raised approximately $15.4 million in gross proceeds during 2025 and early 2026, including $4.125 million from a December 2025 private placement with insider participation, ending 2025 with $7.5 million in cash and cash equivalents and an expected cash runway into the first quarter of 2027. The company also summarized positive topline Phase 3 STAR‑1 data for its XYNGARI acne program from early 2025 but noted it has withdrawn the IND to fully pursue its new DTC strategy, and it reported a narrowed 2025 net loss of $7.6 million on lower R&D spending and higher marketing‑driven SG&A costs compared to 2024.

Filing Facts

CIK

1853816

Ticker

-

Form

8K

Source Type

sec

Accession

0001493152-26-012991

Alert Tier

6